Zepbound vs Wegovy: Uses, Results, Forms and Risks
Compare Zepbound and Wegovy by molecule, current U.S. forms and indications, SURMOUNT-5 results, safety and global brand differences.
Zepbound vs Wegovy
Zepbound contains tirzepatide and activates GIP and GLP-1 receptors; Wegovy contains semaglutide and activates the GLP-1 receptor. SURMOUNT-5 found greater average weight reduction with the studied maximum-tolerated injectable tirzepatide regimens than with the studied injectable semaglutide regimens in adults with obesity without diabetes, but that trial did not compare every current Wegovy form, dose or product-specific outcome claim. Choice still depends on the exact local product, indication, health history, monitoring, tolerability, access and prescriber.
An evidence-first comparison sequence
A current comparison has three layers: what each U.S. product label authorizes now, what SURMOUNT-5 directly tested in 2025 and what the same molecules are called or authorized in another country. Mixing those layers produces a confident but outdated answer.
Separate molecule, brand and form
Zepbound is injectable tirzepatide. Current U.S. Wegovy labeling includes semaglutide injection and tablets, with form-specific populations and instructions.
Keep outcome claims product-specific
Both brands address chronic weight management in defined adults, while their additional U.S. indications differ. Wegovy form and age also matter; Zepbound pediatric safety and effectiveness are not established.
Read SURMOUNT-5 inside its protocol
The 72-week open-label trial randomized 751 adults with obesity without type 2 diabetes to maximum-tolerated weekly injectable tirzepatide or semaglutide regimens.
Return suitability to clinical care
A prescriber must connect indication, other medicines, conditions, warnings, pregnancy context, monitoring, adverse effects, supply and cost to the exact local product.
The bars organize comparison priority only. They are not dose rankings, efficacy scores, safety ratings, switching instructions or personal-result forecasts.
Why the 2025 head-to-head trial is not the whole 2026 product comparison
Zepbound contains tirzepatide, which activates GIP and GLP-1 receptors. Wegovy contains semaglutide, a GLP-1 receptor agonist. Receptor activity is a pharmacologic distinction, not a stand-alone rule for personal suitability or tolerability.
SURMOUNT-5 directly compared maximum-tolerated weekly injections for 72 weeks in adults with obesity without diabetes. The trial reported mean weight changes of -20.2% with tirzepatide and -13.7% with semaglutide, but it did not test Wegovy tablets, Wegovy HD 7.2 mg, adolescents, diabetes or product-specific cardiovascular, liver and sleep-apnea outcomes.
Current labels have moved beyond the two injections in that protocol. Wegovy's U.S. family includes injection and tablets with form- and population-specific uses; Zepbound remains an injectable adult product with its own weight-management and obstructive-sleep-apnea indications. Country authorization, supply and reimbursement add another layer.
Deeper visual interpretation
The direct trial answers a real efficacy question, but the current products answer more questions than that trial tested. Keep the 2025 protocol, the 2026 labels and the local market in separate columns.
| Question | Zepbound | Wegovy |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Receptor activity | GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Current form set | Injection | Injection and tablets; instructions and populations are form-specific |
| Weight-management population | Defined adults; pediatric safety and effectiveness not established | Defined adults; injection also has an established obesity indication from age 12 |
| Additional U.S. label context | Moderate-to-severe obstructive sleep apnea in adults with obesity | Product- and form-specific cardiovascular and MASH indications in defined adults |
| Protocol item | Direct evidence | Boundary in a current comparison |
|---|---|---|
| Population | 751 adults with obesity without type 2 diabetes | Not adolescents, people with diabetes or every labeled population |
| Regimens | Maximum-tolerated tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg, injected weekly | Not Wegovy tablets, Wegovy HD 7.2 mg or a switch schedule |
| Duration and design | 72 weeks, randomized, open-label, controlled | Not lifetime treatment, blinded comparison or personal forecast |
| Mean weight result | -20.2% with tirzepatide and -13.7% with semaglutide at week 72 | A trial average for these regimens, not a guaranteed result or dose recommendation |
| Funding | Funded by Eli Lilly | Funding belongs in interpretation; it does not erase the randomized result |
Use the comparison without turning it into a prescription
- Match the exact current product
Write country, brand, molecule, form, strength and label revision before using an indication or instruction.
- Name the outcome that matters
Separate long-term weight management, cardiovascular risk reduction, MASH, obstructive sleep apnea and another clinical goal.
- Check trial fit
Age, diabetes status, formulation, tolerated regimen, duration and outcome decide whether SURMOUNT-5 directly answers the question.
- Compare safety without false percentages
Adverse-event rates from separate label programs cannot be ranked as if one shared population produced every number.
- Leave transition and access with the right professionals
The prescriber handles clinical suitability and any change; the licensed pharmacy and payer verify supply, authorization and cost.
How to interpret the comparison
This sequence separates molecule, approved use, trial population, dose studied and safety context. It does not decide which medicine is appropriate, convert doses or provide personal medicine-change instructions.
Compare the exact local label and the exact study population. Results from type 2 diabetes trials and obesity trials answer different questions and should not be treated as interchangeable brand claims.
Prescription comparison and safety principles
- Record country, exact brand, active ingredient, dosage form, strength and current label before comparing instructions.
- Keep the SURMOUNT-5 averages attached to its adult population, injectable regimens, 72-week duration, open-label design and industry funding; they are not a personal forecast.
- Do not copy milligrams, escalation, missed-dose, device or transition instructions between tirzepatide and semaglutide—or between Wegovy injection and tablets.
- Verify licensed prescribing, pharmacy, storage and sealed supply. Treat imported, compounded or online products as a separate authorization and safety question.
Seek urgent care for severe allergic symptoms, breathing difficulty, fainting or another emergency. Severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, symptoms of low glucose or another serious reaction need prompt clinical advice under the exact local plan. Do not combine, stop, switch or convert Zepbound and Wegovy using this comparison.
Why your timeline may differ
Questions to ask before treatment
- Which country, brand, form, strength and label revision apply?
- Does the clinical goal match the product-specific indication?
- Does SURMOUNT-5 match the person's age, diabetes status, formulation and outcome question?
- Which health conditions, medicines and warning signs change monitoring?
- Who will verify supply and manage any clinician-directed transition?
Zepbound is a U.S. brand and not a universal name for weight-management tirzepatide. The U.K., for example, uses Mounjaro for locally authorized tirzepatide weight management. Wegovy forms, indications and availability also vary. Use the official information where the medicine is supplied.
Find official checks for 12 marketsHow this guide was made
5 named sources support the main claims. Each link explains how it was used, with public agencies, professional bodies or primary research preferred.
AI may assist with research organization, drafting and translation, but it is not treated as a source or credential. Read the editorial standards.
Stage bars organize a relative sequence. Original editorial illustrations are conceptual and are not clinical measurements, outcome percentages or personal forecasts.
This version has editorial evidence review, not medical review attributed to a named clinician. It does not replace an individual assessment. Editorial accountability.
Sources
- DailyMed: U.S. Zepbound Prescribing Information (April 2026)
Current U.S. tirzepatide product indications for adult weight management and obesity-related obstructive sleep apnea, forms, limitations, warnings and administration.
- FDA: U.S. Wegovy Prescribing Information (June 2026)
Current combined U.S. information for Wegovy injection and tablets, including form-specific weight, cardiovascular and MASH uses, populations and instructions.
- SURMOUNT-5: Tirzepatide Compared with Semaglutide for Obesity
Randomized open-label 72-week trial in 751 adults with obesity without type 2 diabetes comparing maximum-tolerated weekly injectable tirzepatide and semaglutide regimens; funded by Eli Lilly.
- UK MHRA: GLP-1 Medicines for Weight Loss and Diabetes
Current U.K. brand and authorization context showing Wegovy and Mounjaro rather than a universal U.S. Zepbound brand map.
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Risks involving unapproved, compounded, fraudulent and counterfeit products, dosing errors, storage and licensed supply.
Frequently asked questions
What should I know about Zepbound vs Wegovy?
Zepbound contains tirzepatide and activates GIP and GLP-1 receptors; Wegovy contains semaglutide and activates the GLP-1 receptor. SURMOUNT-5 found greater average weight reduction with the studied maximum-tolerated injectable tirzepatide regimens than with the studied injectable semaglutide regimens in adults with obesity without diabetes, but that trial did not compare every current Wegovy form, dose or product-specific outcome claim. Choice still depends on the exact local product, indication, health history, monitoring, tolerability, access and prescriber.
Why can the timeline differ from person to person?
Treatment type, depth, technique, anatomy, skin and tissue response, health history, medication, aftercare and complications can all change timing. The treating professional’s instructions take priority over a general guide.
When should I contact a professional?
Seek urgent care for severe allergic symptoms, breathing difficulty, fainting or another emergency. Severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, symptoms of low glucose or another serious reaction need prompt clinical advice under the exact local plan. Do not combine, stop, switch or convert Zepbound and Wegovy using this comparison.
Continue through the global GLP-1 comparison map
Keep the direct trial, current brand labels, side effects, private planning and appearance evidence in separate records.
Read the Wegovy side-effects guide Open the global GLP-1 evidence hub Compare Mounjaro and Zepbound Compare Wegovy and MounjaroExplore the complete GLP-1 beauty and body guide
Move between product identity, side-effect timing, facial documentation, hair-loss evidence, exercise safety and private tools without turning appearance into a diagnosis or prescription decision.
Open the GLP-1 topic hub Read the GLP-1 side-effects timelineRelated beauty guides
View BodyLiposuction Recovery Timeline: Week 1 to Month 6
A visual guide to bruising, swelling, activity limits and when body-contour results become easier to see after liposuction.
Read next BODYNonsurgical Body Contouring: Recovery and Results Timeline
Compare fat freezing, heat, ultrasound and magnetic body-contouring timelines, side effects, results and device-specific risks.
Read next BODYMounjaro Face: Facial Volume Changes, Evidence and Options
What ‘Mounjaro face’ means, why facial volume may change with substantial weight loss, what evidence can and cannot prove, and how to plan a qualified review.
Read nextThis guide is for general education only. It is not medical advice, diagnosis, a treatment recommendation or a prediction of individual results. BeautiNext is not a clinic. Seek care from an appropriately qualified professional.